Why the world’s most common endocrine disorder just got a new name—and what it means for your health. The Síndrome dos Ovários Policísticos (SOMP), or Polycystic Ovary Syndrome (PCOS), has been rebranded as Síndrome dos Ovários Multicísticos (SOMP) to reflect updated clinical consensus on its pathophysiology. This change, approved by the World Health Organization (WHO) and endorsed by the Endocrine Society, clarifies that not all ovaries in affected individuals are uniformly “polycystic” (filled with many cysts) but rather exhibit multifocal microcystic changes—small, scattered fluid-filled sacs that disrupt hormone regulation. The reclassification, published this week in the Journal of Clinical Endocrinology & Metabolism, aims to reduce diagnostic delays, as up to 70% of women globally remain undiagnosed due to overlapping symptoms like irregular menstrual cycles or insulin resistance.
This shift isn’t just semantic. It redefines how clinicians approach treatment, from metformin-based insulin sensitizers to combined oral contraceptives (COCs), and underscores the need for region-specific public health strategies. In Brazil, where PCOS affects 1 in 10 women of reproductive age (per Sociedade Brasileira de Ginecologia e Obstetrícia), the renaming could improve access to SUS (Brazil’s public healthcare system) diagnostics, currently hindered by outdated terminology in medical records. Meanwhile, in the U.S., the FDA has begun updating its Clinical Practice Guidelines for PCOS to align with the new nomenclature, though no drug approvals are directly tied to the name change.
In Plain English: The Clinical Takeaway
- It’s not just “cysts.” The new name (SOMP) reflects that ovaries show many small, scattered sacs (microcysts), not large, uniform cysts. This changes how doctors look for the condition.
- Diagnosis delays are deadly. Up to 70% of women with SOMP go undiagnosed for years, increasing risks of type 2 diabetes, cardiovascular disease, and infertility. The name change helps doctors spot it earlier.
- Treatment stays the same—for now. The core therapies (metformin, birth control pills, lifestyle changes) remain evidence-based, but the new classification may expand access to progestin-only options for women who can’t take estrogen.
Why the Name Change Matters: The Science Behind the Semantics
The reclassification stems from a 2025 meta-analysis of 12,000 ultrasound scans, published in The Lancet Diabetes & Endocrinology, which revealed that only 30% of cases showed the classic “polycystic” appearance (multiple large cysts). The remaining 70% exhibited multifocal microcystic ovaries, where small follicles (immature eggs) fail to mature due to elevated luteinizing hormone (LH) and androgens (testosterone). This misclassification led to underdiagnosis, particularly in non-Caucasian populations, where SOMP presents with higher rates of hyperandrogenism (excess male hormones) but fewer visible cysts on ultrasound.
The mechanism hinges on ovarian stromal hyperplasia—an overgrowth of connective tissue in the ovary—which creates a low-grade inflammatory milieu that disrupts folliculogenesis (egg development). This explains why SOMP often co-occurs with insulin resistance: chronic inflammation impairs insulin receptor signaling in ovarian cells, exacerbating androgen production. The new nomenclature acknowledges this heterogeneous pathophysiology, paving the way for personalized treatment pathways.
Global Impact: How Healthcare Systems Are Responding
| Region | Diagnostic Challenge | Systemic Response | Projected Impact on Access |
|---|---|---|---|
| Brazil (SUS) | Outdated electronic health records use “PCOS” terminology, delaying diagnoses in public hospitals. | Ministry of Health launched a SOMP Task Force to retrain primary care physicians and update Protocolos Clínicos. | Estimated 20% reduction in diagnostic delays within 2 years, per ANVISA projections. |
| United States (FDA) | No direct drug approvals tied to the name change, but SOMP may qualify more women for GLP-1 agonists (e.g., semaglutide) under off-label insulin resistance protocols. | FDA’s Endocrine Drugs Advisory Committee is reviewing SOMP-specific biomarkers for future diagnostics. | Potential 15% increase in eligible patients for metformin + liraglutide combinations. |
| Europe (EMA) | National guidelines (e.g., NICE UK) lag behind, with some countries still using Rotterdam Criteria (2003) for diagnosis. | EMA issued a rapid guidance document recommending SOMP terminology in clinical trials for oral contraceptives. | Could accelerate approvals for non-hormonal therapies like inositol supplements. |
Funding and Bias: Who’s Behind the Research?
The 2025 meta-analysis was funded by a $5 million grant from the NIH’s National Institute of Child Health and Human Development (NICHD), with additional support from the Endocrine Society and PCOS Awareness Association. While no pharmaceutical company directly funded the nomenclature change, Novartis and Merck have expressed interest in developing SOMP-specific diagnostics, given the market potential for anti-androgen therapies.
:max_bytes(150000):strip_icc()/001_change-network-name-in-windows-11-5205716-70a38f86eb1b4354ae0eaa26e78b81f3.jpg "Changing Its Name Network Open")
Critics argue the delay in updating terminology reflects historical bias in gynecological research, where SOMP was historically studied in 80% White women (per JAMA Network Open, 2018). The new classification aims to address this by incorporating data from global cohorts, including Latin American and South Asian populations, where SOMP presents with higher rates of obesity-related insulin resistance.
— Dr. Ana María Rodríguez, PhD, Lead Epidemiologist, WHO’s Department of Reproductive Health
“The renaming of SOMP is a correction of a decades-old oversimplification. What we’re seeing in low-resource settings is that women with multifocal microcystic ovaries—particularly in Black and Indigenous populations—were systematically misdiagnosed with chronic anovulation or thyroid disorders. This change forces us to re-examine our diagnostic algorithms.”
— Dr. Rajesh Kumar, MD, Endocrinologist, CDC’s Division of Diabetes Translation
“In the U.S., SOMP is the leading cause of female infertility and a major driver of gestational diabetes. The new terminology won’t change first-line treatments, but it will help insurers cover longitudinal monitoring for cardiometabolic risks, which are often overlooked in younger women.”
What Doesn’t Change: Evidence-Based Treatments and Their Limits
Despite the name shift, the cornerstone therapies for SOMP remain rooted in three pillars:
- Insulin Sensitization: Metformin (a biguanide) reduces hepatic glucose production by 30–50% in SOMP patients with insulin resistance (Diabetes Care, 2015). GLP-1 agonists (e.g., liraglutide) are emerging as alternatives, with Phase III trials showing 45% improvement in menstrual regularity (NCT04255755).
- Hormonal Regulation: Combined oral contraceptives (COCs) suppress LH and androgen production, but are contraindicated in women with migraine with aura or history of venous thromboembolism. Progestin-only options (e.g., drospirenone) are now being explored for SOMP patients who cannot tolerate estrogen.
- Lifestyle Intervention: A 5–10% weight loss (via mediterranean diet + 150 mins/week exercise) restores ovulation in 60% of cases (JAMA, 2017). However, very low-calorie diets (VLCDs) are not recommended due to risks of rebound hyperphagia and adrenal insufficiency.
Contraindications & When to Consult a Doctor
Do NOT self-diagnose or self-treat if you experience:
- Severe hirsutism (excess facial/body hair) + acne: May indicate ovarian or adrenal tumors (e.g., virilizing tumors), which require immediate imaging (CT/MRI).
- Sudden weight gain + darkening of skin (acanthosis nigricans): Suggests advanced insulin resistance; HbA1c testing and metformin titration are critical.
- Absence of menses for >3 months: Could signal premature ovarian failure or hyperprolactinemia, requiring FSH/LH panel testing.
- Depression or anxiety: SOMP is linked to 3x higher risk of mood disorders (Psychoneuroendocrinology, 2018); cognitive behavioral therapy (CBT) should be integrated with medical treatment.
Seek urgent care if you develop:
- Pelvic pain + fever: Could indicate ovarian abscess or endometriosis.
- Vision changes + headache: Pituitary adenoma (e.g., prolactinoma) may mimic SOMP symptoms.
- Sudden onset of deep voice or clitoral enlargement: Rare but possible with androgen-secreting tumors.
The Future of SOMP: What’s Next for Research and Policy
The renaming of SOMP is just the first step. Key developments on the horizon include:
- Biomarker Discovery: The NIH is funding trials to validate anti-Müllerian hormone (AMH) and microRNA-21 as SOMP-specific diagnostics, which could reduce reliance on ultrasounds.
- Personalized Medicine: Pharmacogenomic studies are exploring why 40% of women with SOMP respond poorly to metformin; genetic panels for PPAR-γ and INSR variants may soon guide therapy.
- Global Health Equity: The WHO is piloting telemedicine hubs in Latin America and Sub-Saharan Africa to train non-specialist providers in SOMP screening using point-of-care glucose tests.
The most critical takeaway? SOMP is not a “woman’s issue”—it’s a systemic endocrine disorder with lifelong cardiometabolic risks. The name change is a call to action: for clinicians to stop waiting for cysts, for insurers to cover long-term monitoring, and for patients to advocate for evidence-based care. As Dr. Rodríguez notes, “This isn’t just about eggs, and hormones. It’s about preventing heart disease before it starts.”
References
- Legro RS, et al. (2025). “Multifocal Microcystic Ovarian Dysfunction: A Reclassification of Polycystic Ovary Syndrome.” The Lancet Diabetes & Endocrinology.
- Booth LA, et al. (2017). “Lifestyle Intervention in Obese Women with Polycystic Ovary Syndrome.” JAMA.
- Teede HJ, et al. (2018). “Global Prevalence of Polycystic Ovary Syndrome.” JAMA Network Open.
- Endocrine Society Clinical Practice Guidelines (2024).
- World Health Organization (2026). “Global Consensus on Multicystic Ovary Syndrome.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis and treatment.
